US FDA Panel To Weigh Whether Copiktra’s Benefit-Risk Profile In Hematologic Cancers Has Changed

 
• By Sue Sutter
Risk outweighs benefit
FDA thinks the risks of Copiktra may now outweigh the drug's benefits in two hematologic malignancies. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers